Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

164
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
164
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

170
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
170
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

252
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
252
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

239
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
239

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial injury with capillary leak: A final common pathway in acute AAV toxicity?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

The dose makes the poison: Mechanisms of cytotoxicity of high-dose AAV vectors.

Molecular therapy. Advances·2026
Same author

Optimization of Alpha-1 Antitrypsin Expression from Adeno-Associated Virus Vectors.

Human gene therapy·2026
Same author

Letter to the Editor. Intrathalamic gene delivery.

Journal of neurosurgery·2026
Same author

Immune Toxicities in AAV Gene Therapy: Overview for Clinicians.

International journal of molecular sciences·2026
Same author

AAV9 Gene Therapy in Type II GM1 Gangliosidosis - A Phase 1-2 Trial.

The New England journal of medicine·2026

Related Experiment Video

Updated: Jul 8, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.7K

Alpha-1 Antitrypsin Deficiency.

Alisha M Gruntman1, Wen Xue1, Terence R Flotte2

  • 1Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, MA, USA.

Methods in Molecular Biology (Clifton, N.J.)
|December 18, 2023
PubMed
Summary
This summary is machine-generated.

Alpha-1 antitrypsin (AAT) deficiency, a genetic disorder caused by a SERPINA1 mutation, is a prime candidate for gene editing therapies. Its commonality and specific mutation profile make it highly targetable for therapeutic intervention.

Keywords:
Alpha-1 antitrypsinCRISPR–Cas9EmphysemaGene editingGene therapyLiverLungVector

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.3K
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.4K

Related Experiment Videos

Last Updated: Jul 8, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.7K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.3K
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.4K

Area of Science:

  • Genetics
  • Molecular Biology
  • Therapeutic Development

Background:

  • Alpha-1 antitrypsin (AAT) deficiency is a prevalent monogenic disorder.
  • A strong founder effect exists for a specific missense mutation in the SERPINA1 gene.
  • AAT is a key circulating serum anti-protease primarily produced by hepatocytes.

Purpose of the Study:

  • To highlight Alpha-1 antitrypsin (AAT) deficiency as an attractive target for gene editing.
  • To underscore the suitability of AAT deficiency for various therapeutic gene editing strategies.

Main Methods:

  • The abstract does not specify methods, but implies the study focuses on the genetic and molecular characteristics of AAT deficiency.
  • Discussion of gene editing approaches for AAT deficiency.

Main Results:

  • The specific genetic features of AAT deficiency, including a common mutation and founder effect, are identified.
  • These characteristics make AAT deficiency a highly promising target for gene editing.

Conclusions:

  • Alpha-1 antitrypsin (AAT) deficiency presents a compelling case for the application of gene editing technologies.
  • The genetic underpinnings of AAT deficiency support diverse therapeutic gene editing strategies.